Sprite

Aura GT

Small Volume AAV Characterization

Gain unprecedented insight into gene therapy development with Aura GT. Just 5 µL of sample is all you need to evaluate capsid and viral vector aggregates, so you can identify stability issues early.

What will you discover with your extra sample?

AuraGT particle analyzer
molecule_icon

Viral Vector Aggregation

liquid_drop_icon

5 µL Volume

polygon_icon

DNA Leakage Monitoring

clock

1 Minute Per Sample

Why Choose Aura GT?

There’s no question that adeno-associated viruses (AAVs) have revolutionized gene therapy product development.

But with a limited amount of material available, you may have hesitated about using your precious sample for aggregate testing—until now.

Aura GT is the first and only system designed to detect, count, and characterize AAV particles with just 5 µL.

Analyze small volumes. You only need 5 µL of sample, which allows you to start characterizing particles in early phase development.

Easily Quantify and Identify AAV Particles

AAVs are known to form large, subvisible aggregates that cannot be easily predicted or quantified, making it difficult to assess their impact on patients. To make things even more convoluted, unstable AAVs can aggregate in unpredictable shapes and forms.

Luckily, there’s an easier way to identify and characterize AAV aggregates with Aura GT. Now you can characterize your AAV particles with the lowest volume requirements, highest throughput, and gain insight into their stability.

Root_cause
plate-pipette

Identify Root Cause and Characterize AAV Particles at Low Volume

Researchers have long sought to identify the root cause of unstable AAV particles. This challenge has been compounded by legacy systems that are unable to perform low volume SVP analysis or interrogate for DNA content.

In one 5µL assay, Aura GT overcomes this hurdle.

Leverage the power of fluorescent dyes such as Thioflavin T (ThT) and SYBR™ Gold to confidently identify capsid aggregates and DNA in your gene therapy sample with FMM. Make more educated AAV candidate decisions and learn the root causes of aggregation at the very beginning of your process.

Gain Valuable Insights in Hours, Not Months

Get your gene therapy products to market at lightning speed with Aura GT.

Instead of waiting months to see results, Aura GT’s 96-well particle screening assay can give you useful information in just a few hours.

Make direct comparisons between different formulations, AAV serotypes and stability, storage conditions, and lots.

gain_valuable

Key Specifications

Imaging Area 24.6 mm2
Optics 4x objective
Minimum volume 5 μL (assay dependent)
Resolution 1.0 pixel/μm
Detectable size range Range from >1 μm (ECD) to <5 mm (ECD)
BMI read time 1 minute/sample
FMM read time 30 seconds/sample
Software Particle VUE 4.x all-in-one software suite (image capture and analysis)

Related Documents

  • Sprite

    Aura Family Brochure

  • Sprite

    App Note: Is Your AAV Payload Impacting Stability?

  • Sprite

    App Note: Analysis Of Subvisible & Visible Aggregation In Lentiviral Vectors With Aura GT

  • Sprite

    Watch webinar: Characterizing the Stability of Gene Therapy Products at Ultra Low Volume

Ready to bring fast, decisive, low volume particle characterization to all of your gene therapy development and manufacturing workflows? Get in touch to request a quote.

Particle Vue Software

Get particle analysis answers in just a few clicks with flexible, easy-to-use Particle Vue Software.